Intrinsic value of Dimension Therapeutics - DMTX

Previous Close

$1.23

  Intrinsic Value

$0.62

stock screener

  Rating & Target

sell

-50%

  Value-price divergence*

0%

Previous close

$1.23

 
Intrinsic value

$0.62

 
Up/down potential

-50%

 
Rating

sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of DMTX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  37.50
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  11
  18
  27
  41
  59
  83
  114
  154
  202
  260
  328
  407
  498
  600
  714
  839
  976
  1,125
  1,284
  1,454
  1,635
  1,826
  2,027
  2,238
  2,459
  2,690
  2,931
  3,182
  3,442
  3,714
  3,996
Variable operating expenses, $m
 
  94
  146
  218
  316
  447
  614
  824
  1,082
  1,392
  1,758
  2,184
  2,670
  3,218
  3,829
  4,502
  5,237
  6,032
  6,887
  7,800
  8,770
  9,795
  10,874
  12,006
  13,192
  14,430
  15,722
  17,066
  18,465
  19,920
  21,432
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  61
  94
  146
  218
  316
  447
  614
  824
  1,082
  1,392
  1,758
  2,184
  2,670
  3,218
  3,829
  4,502
  5,237
  6,032
  6,887
  7,800
  8,770
  9,795
  10,874
  12,006
  13,192
  14,430
  15,722
  17,066
  18,465
  19,920
  21,432
Operating income, $m
  -49
  -77
  -119
  -177
  -257
  -363
  -499
  -670
  -880
  -1,133
  -1,431
  -1,777
  -2,172
  -2,618
  -3,115
  -3,663
  -4,260
  -4,908
  -5,603
  -6,346
  -7,135
  -7,969
  -8,847
  -9,768
  -10,733
  -11,740
  -12,791
  -13,885
  -15,023
  -16,207
  -17,437
EBITDA, $m
  -47
  -76
  -117
  -175
  -255
  -359
  -494
  -663
  -870
  -1,120
  -1,414
  -1,756
  -2,147
  -2,588
  -3,079
  -3,621
  -4,212
  -4,851
  -5,539
  -6,273
  -7,053
  -7,877
  -8,745
  -9,656
  -10,610
  -11,606
  -12,644
  -13,726
  -14,851
  -16,021
  -17,237
Interest expense (income), $m
  0
  0
  1
  2
  3
  5
  8
  11
  15
  20
  25
  32
  40
  50
  60
  72
  84
  98
  113
  130
  147
  165
  185
  205
  227
  249
  273
  297
  323
  349
  377
Earnings before tax, $m
  -49
  -77
  -120
  -179
  -261
  -368
  -507
  -681
  -895
  -1,152
  -1,456
  -1,809
  -2,212
  -2,668
  -3,175
  -3,734
  -4,345
  -5,006
  -5,717
  -6,476
  -7,282
  -8,134
  -9,031
  -9,973
  -10,959
  -11,989
  -13,063
  -14,182
  -15,346
  -16,556
  -17,813
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -49
  -77
  -120
  -179
  -261
  -368
  -507
  -681
  -895
  -1,152
  -1,456
  -1,809
  -2,212
  -2,668
  -3,175
  -3,734
  -4,345
  -5,006
  -5,717
  -6,476
  -7,282
  -8,134
  -9,031
  -9,973
  -10,959
  -11,989
  -13,063
  -14,182
  -15,346
  -16,556
  -17,813

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  78
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  94
  57
  88
  132
  192
  270
  372
  499
  655
  843
  1,064
  1,322
  1,616
  1,948
  2,317
  2,725
  3,170
  3,651
  4,169
  4,721
  5,308
  5,928
  6,582
  7,267
  7,985
  8,734
  9,516
  10,330
  11,177
  12,057
  12,973
Adjusted assets (=assets-cash), $m
  16
  57
  88
  132
  192
  270
  372
  499
  655
  843
  1,064
  1,322
  1,616
  1,948
  2,317
  2,725
  3,170
  3,651
  4,169
  4,721
  5,308
  5,928
  6,582
  7,267
  7,985
  8,734
  9,516
  10,330
  11,177
  12,057
  12,973
Revenue / Adjusted assets
  0.688
  0.316
  0.307
  0.311
  0.307
  0.307
  0.306
  0.309
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
  0.308
Average production assets, $m
  6
  9
  14
  20
  30
  42
  57
  77
  101
  130
  164
  204
  249
  300
  357
  420
  488
  562
  642
  727
  817
  913
  1,014
  1,119
  1,230
  1,345
  1,465
  1,591
  1,721
  1,857
  1,998
Working capital, $m
  64
  -2
  -3
  -4
  -6
  -8
  -11
  -15
  -20
  -26
  -33
  -41
  -50
  -60
  -71
  -84
  -98
  -112
  -128
  -145
  -163
  -183
  -203
  -224
  -246
  -269
  -293
  -318
  -344
  -371
  -400
Total debt, $m
  7
  24
  52
  91
  144
  215
  306
  419
  559
  727
  926
  1,156
  1,419
  1,716
  2,047
  2,412
  2,810
  3,241
  3,704
  4,199
  4,724
  5,279
  5,864
  6,477
  7,119
  7,790
  8,490
  9,218
  9,976
  10,764
  11,584
Total liabilities, $m
  34
  51
  79
  118
  171
  242
  333
  446
  586
  754
  953
  1,183
  1,446
  1,743
  2,074
  2,439
  2,837
  3,268
  3,731
  4,226
  4,751
  5,306
  5,891
  6,504
  7,146
  7,817
  8,517
  9,245
  10,003
  10,791
  11,611
Total equity, $m
  60
  6
  9
  14
  20
  28
  39
  52
  69
  88
  112
  139
  170
  205
  243
  286
  333
  383
  438
  496
  557
  622
  691
  763
  838
  917
  999
  1,085
  1,174
  1,266
  1,362
Total liabilities and equity, $m
  94
  57
  88
  132
  191
  270
  372
  498
  655
  842
  1,065
  1,322
  1,616
  1,948
  2,317
  2,725
  3,170
  3,651
  4,169
  4,722
  5,308
  5,928
  6,582
  7,267
  7,984
  8,734
  9,516
  10,330
  11,177
  12,057
  12,973
Debt-to-equity ratio
  0.117
  4.020
  5.610
  6.580
  7.180
  7.570
  7.830
  8.010
  8.130
  8.220
  8.280
  8.330
  8.360
  8.390
  8.410
  8.430
  8.440
  8.450
  8.460
  8.470
  8.480
  8.480
  8.480
  8.490
  8.490
  8.490
  8.500
  8.500
  8.500
  8.500
  8.500
Adjusted equity ratio
  -1.125
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105
  0.105

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -49
  -77
  -120
  -179
  -261
  -368
  -507
  -681
  -895
  -1,152
  -1,456
  -1,809
  -2,212
  -2,668
  -3,175
  -3,734
  -4,345
  -5,006
  -5,717
  -6,476
  -7,282
  -8,134
  -9,031
  -9,973
  -10,959
  -11,989
  -13,063
  -14,182
  -15,346
  -16,556
  -17,813
Depreciation, amort., depletion, $m
  2
  1
  1
  2
  3
  4
  6
  8
  10
  13
  16
  20
  25
  30
  36
  42
  49
  56
  64
  73
  82
  91
  101
  112
  123
  135
  147
  159
  172
  186
  200
Funds from operations, $m
  -52
  -76
  -118
  -177
  -258
  -364
  -501
  -673
  -885
  -1,139
  -1,440
  -1,789
  -2,188
  -2,638
  -3,139
  -3,692
  -4,296
  -4,950
  -5,652
  -6,403
  -7,200
  -8,043
  -8,930
  -9,861
  -10,836
  -11,855
  -12,917
  -14,023
  -15,173
  -16,370
  -17,614
Change in working capital, $m
  -4
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
Cash from operations, $m
  -48
  -75
  -117
  -176
  -256
  -362
  -498
  -669
  -880
  -1,133
  -1,433
  -1,781
  -2,179
  -2,627
  -3,128
  -3,680
  -4,282
  -4,935
  -5,637
  -6,386
  -7,182
  -8,023
  -8,910
  -9,840
  -10,814
  -11,832
  -12,893
  -13,998
  -15,147
  -16,343
  -17,585
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -10
  -13
  -16
  -20
  -25
  -30
  -36
  -42
  -49
  -56
  -64
  -73
  -82
  -91
  -101
  -112
  -123
  -135
  -147
  -159
  -172
  -186
New CAPEX, $m
  -7
  -3
  -5
  -7
  -9
  -12
  -16
  -20
  -24
  -29
  -34
  -40
  -45
  -51
  -57
  -63
  -69
  -74
  -80
  -85
  -90
  -96
  -101
  -106
  -111
  -115
  -120
  -125
  -130
  -136
  -141
Cash from investing activities, $m
  -54
  -4
  -6
  -8
  -11
  -15
  -20
  -26
  -32
  -39
  -47
  -56
  -65
  -76
  -87
  -99
  -111
  -123
  -136
  -149
  -163
  -178
  -192
  -207
  -223
  -238
  -255
  -272
  -289
  -308
  -327
Free cash flow, $m
  -102
  -79
  -123
  -184
  -267
  -377
  -518
  -695
  -912
  -1,172
  -1,480
  -1,837
  -2,244
  -2,703
  -3,215
  -3,778
  -4,393
  -5,058
  -5,772
  -6,535
  -7,345
  -8,201
  -9,102
  -10,047
  -11,037
  -12,070
  -13,148
  -14,270
  -15,437
  -16,651
  -17,912
Issuance/(repayment) of debt, $m
  5
  19
  28
  39
  53
  70
  91
  114
  140
  168
  198
  230
  263
  297
  331
  365
  398
  431
  463
  495
  525
  555
  585
  614
  642
  671
  700
  728
  758
  788
  819
Issuance/(repurchase) of shares, $m
  0
  79
  123
  184
  267
  377
  518
  694
  911
  1,172
  1,479
  1,836
  2,243
  2,703
  3,214
  3,777
  4,392
  5,057
  5,771
  6,534
  7,343
  8,199
  9,100
  10,045
  11,035
  12,068
  13,145
  14,267
  15,435
  16,648
  17,910
Cash from financing (excl. dividends), $m  
  5
  98
  151
  223
  320
  447
  609
  808
  1,051
  1,340
  1,677
  2,066
  2,506
  3,000
  3,545
  4,142
  4,790
  5,488
  6,234
  7,029
  7,868
  8,754
  9,685
  10,659
  11,677
  12,739
  13,845
  14,995
  16,193
  17,436
  18,729
Total cash flow (excl. dividends), $m
  -97
  19
  28
  39
  53
  70
  90
  113
  139
  168
  198
  230
  262
  296
  330
  364
  397
  430
  462
  493
  524
  553
  583
  612
  640
  669
  697
  726
  756
  786
  817
Retained Cash Flow (-), $m
  46
  -79
  -123
  -184
  -267
  -377
  -518
  -694
  -911
  -1,172
  -1,479
  -1,836
  -2,243
  -2,703
  -3,214
  -3,777
  -4,392
  -5,057
  -5,771
  -6,534
  -7,343
  -8,199
  -9,100
  -10,045
  -11,035
  -12,068
  -13,145
  -14,267
  -15,435
  -16,648
  -17,910
Prev. year cash balance distribution, $m
 
  56
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -4
  -95
  -145
  -214
  -306
  -427
  -581
  -772
  -1,004
  -1,282
  -1,606
  -1,981
  -2,406
  -2,884
  -3,413
  -3,995
  -4,627
  -5,309
  -6,041
  -6,820
  -7,646
  -8,517
  -9,434
  -10,394
  -11,399
  -12,448
  -13,541
  -14,679
  -15,863
  -17,093
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -4
  -87
  -126
  -176
  -237
  -310
  -392
  -483
  -577
  -672
  -763
  -845
  -915
  -968
  -1,002
  -1,015
  -1,007
  -978
  -930
  -867
  -791
  -707
  -618
  -529
  -443
  -363
  -291
  -227
  -173
  -129
Current shareholders' claim on cash, %
  100
  3.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression in patients with hemophilia B; DTX201, a gene therapy program for the treatment of hemophilia A; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; and DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase. Dimension Therapeutics, Inc. was founded in 2013 and is based Cambridge, Massachusetts.

FINANCIAL RATIOS  of  Dimension Therapeutics (DMTX)

Valuation Ratios
P/E Ratio -0.6
Price to Sales 2.8
Price to Book 0.5
Price to Tangible Book
Price to Cash Flow -0.6
Price to Free Cash Flow -0.6
Growth Rates
Sales Growth Rate 37.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 133.3%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 39
Current Ratio 0.2
LT Debt to Equity 8.3%
Total Debt to Equity 11.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -43.2%
Ret/ On Assets - 3 Yr. Avg. -61.5%
Return On Total Capital -56.3%
Ret/ On T. Cap. - 3 Yr. Avg. -41.2%
Return On Equity -59%
Return On Equity - 3 Yr. Avg. 390.6%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -427.3%
EBITDA Margin - 3 Yr. Avg. -428.5%
Operating Margin -454.5%
Oper. Margin - 3 Yr. Avg. -441.8%
Pre-Tax Margin -445.5%
Pre-Tax Margin - 3 Yr. Avg. -438.8%
Net Profit Margin -445.5%
Net Profit Margin - 3 Yr. Avg. -438.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

DMTX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DMTX stock intrinsic value calculation we used $11 million for the last fiscal year's total revenue generated by Dimension Therapeutics. The default revenue input number comes from 2016 income statement of Dimension Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DMTX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DMTX is calculated based on our internal credit rating of Dimension Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dimension Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DMTX stock the variable cost ratio is equal to 536.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DMTX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Dimension Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Dimension Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DMTX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DMTX are equal to 50%.

Life of production assets of 10 years is the average useful life of capital assets used in Dimension Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DMTX is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $60 million for Dimension Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 24.328 million for Dimension Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dimension Therapeutics at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
ONCE Spark Therapeu 76.05 2.73  str.sell
RGNX REGENXBIO 20.00 1.51  str.sell
SGMO Sangamo Therap 10.25 0.45  str.sell
BMRN BioMarin Pharm 80.98 3.63  str.sell
BIIB Biogen 284.42 288.93  hold
PFE Pfizer 32.95 28.58  hold

COMPANY NEWS

▶ Dimension Therapeutics reports 2Q loss   [Aug-08-17 11:51PM  Associated Press]
▶ Dimension Therapeutics Announces Management Change   [Jul-24-17 08:00AM  GlobeNewswire]
▶ Enterome Appoints Mary Thistle to its Board of Directors   [Jul-12-17 03:00AM  PR Newswire]
▶ Cambridge's Dimension slashes headcount after lead drug flops   [Jun-28-17 11:25AM  American City Business Journals]
▶ Dimension Therapeutics reports 1Q loss   [May-10-17 08:10AM  Associated Press]
▶ Despite rocky market, Rockville's Regenxbio on serious growth path   [Mar-02-16 05:20AM  at bizjournals.com]
▶ What recent gene therapy offerings tell us about todays Editas IPO   [Feb-03-16 07:00AM  at bizjournals.com]
Stock chart of DMTX Financial statements of DMTX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.